Müller-Eberhard, 1985 - Google Patents
The killer molecule of complementMüller-Eberhard, 1985
View PDF- Document ID
- 5186003318281282915
- Author
- Müller-Eberhard H
- Publication year
- Publication venue
- Journal of Investigative Dermatology
External Links
Snippet
Cell injury by complement occurs as a consequence of activation of either the classical or the alternative pathway on the surface of a cell. It is accomplished by the membrane attack complex (MAC). Its precursor proteins, C5, C6, C7, C8, and C9, are hydrophilic …
- 230000000295 complement 0 title abstract description 20
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Müller-Eberhard | The killer molecule of complement | |
Podack et al. | Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly | |
Hartgers et al. | DC‐STAMP, a novel multimembrane‐spanning molecule preferentially expressed by dendritic cells | |
DE69533295T3 (en) | Melanoma-associated antigens, epitopes thereof and melanoma-containing vaccines | |
US7659252B2 (en) | Transdermal delivery peptides and method of use thereof | |
JP2008029344A (en) | Novel compound | |
MX2007009219A (en) | Survivin peptide vaccine. | |
US6172201B1 (en) | Cellular receptor for HIV-1 Vpr essential for G2/M phase | |
CN109890411A (en) | Tuberculosis composition and treatment or prevention method lungy | |
WO2014059384A2 (en) | ICAM-1 TARGETING ELPs | |
US6235285B1 (en) | Glycogen phosphorylase from streptococcus pneumoniae | |
JP2004000215A (en) | New topoisomerase iii | |
DE69624586T2 (en) | PEPTIDE VACCINE BASED ON FUSION PROTEINS WITH ONCOGENIC PART | |
CN109970865A (en) | A kind of two-way activation costimulatory molecules receptor of CD137 and application thereof | |
US20220195401A1 (en) | Modified piggybac transposase polypeptide, polynucleotide encoding them, introducing carrier, kit, method of incorporating target sequence into cell genome, and method of producing cell | |
JP4065322B2 (en) | Synthetic peptides and pharmaceutical compositions containing them | |
JPH10309194A (en) | Topoisomerase i | |
CA2991223A1 (en) | Pore-forming peptides and uses thereof | |
CN100480387C (en) | GBS toxin receptor | |
CA2244232A1 (en) | Novel def | |
KR20230156367A (en) | A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases | |
JP2001515363A (en) | Staphylococcus aureus UDP-N-acetylmuramoyl-L-alanine: D-glutamme Triggerase (murD) | |
CA2244239A1 (en) | Novel era | |
US20060270605A1 (en) | Compositions and methods for inhibiting cell growth and modulating gene expression | |
US20230364261A1 (en) | Targeted antigen delivery system and uses thereof |